The text discusses two clinical trials related to the use of Oxaliplatin in cancer treatment. The first trial, PRODIGE 51 - LEANOX, evaluates the impact of adjusting Oxaliplatin dose based on muscle mass on neurotoxicity in colon cancer patients. The second trial, ACOTAS G-098, assesses chest pain in patients with colorectal/esophagogastric adenocarcinoma after treatment with trifluridine/tipiracil +/- oxaliplatin.